11 research outputs found
Arbovirus Epidemiology: The Mystery of Unnoticed Epidemics in Ghana, West Africa
It is evident that all the countries surrounding Ghana have experienced epidemics of key arboviruses of medical importance, such as the recent dengue fever epidemic in Burkina Faso. Therefore, Ghana is considered a ripe zone for epidemics of arboviruses, mainly dengue. Surprisingly, Ghana never experienced the propounded deadly dengue epidemic. Indeed, it is mysterious because the mosquito vectors capable of transmitting the dengue virus, such as Aedes aegypti, were identified in Ghana through entomological investigations. Additionally, cases may be missed, as the diagnostic and surveillance capacities of the country are weak. Therefore, we review the arbovirus situation and outline probable reasons for the epidemic mystery in the country. Most of the recorded cases of arbovirus infections were usually investigated via serology by detecting IgM and IgG immunoglobulins in clinical samples, which is indicative of prior exposure but not an active case. This led to the identification of yellow fever virus and dengue virus as the main circulating arboviruses among the Ghanaian population. However, major yellow fever epidemics were reported for over a decade. It is important to note that the reviewed arboviruses were not frequently detected in the vectors. The data highlight the necessity of strengthening the diagnostics and the need for continuous arbovirus and vector surveillance to provide an early warning system for future arbovirus epidemics
No serological evidence for Zika virus infection and low specificity for anti-Zika virus ELISA in malaria positive individuals among pregnant women from Madagascar in 2010
<div><p>It was previously reported that a malaria infection may interfere with the specificity of a commercial ELISA test against Zika virus (ZIKV). We analyzed 1,216 plasma samples from healthy, pregnant women collected in two sites in Madagascar in 2010 for ZIKV antibodies using a commercial ELISA and for <i>Plasmodium</i> infection by PCR. This screen revealed six putative ZIKV-positive samples by ELISA. These results could not be confirmed by indirect immunofluorescence assays or virus neutralization tests. Four of these six samples were also positive for <i>P</i>. <i>falciparum</i>. We noted that the frequency of malaria positivity was higher in ZIKV-ELISA positive samples (50% and 100% in the two study sites) than ZIKV-negative samples (17% and 10%, respectively), suggesting that malaria may have led to false ZIKV-ELISA positives.</p></div
Malaria Coinfections in Febrile Pediatric Inpatients: A Hospital-Based Study From Ghana
The epidemiology of pediatric febrile illness is shifting in sub-Saharan Africa, but malaria remains a major cause of childhood morbidity and mortality. The present study describes causes of febrile illness in hospitalized children in Ghana and aims to determine the burden of malaria coinfections and their association with parasite densities
Serological test results for four suspected anti-ZIKV seropositive samples from four highland locations in Madagascar.
<p>Serological test results for four suspected anti-ZIKV seropositive samples from four highland locations in Madagascar.</p
Locations in Madagascar, where the plasma samples investigated in this study were collected in 2010.
<p>Locations at seal level (blue dots, n = 433) and in the highlands (red dots, n = 783) were analyzed separately.</p
Limited specificity of commercially available SARSâCoVâ2 IgG ELISAs in serum samples of African origin
Objectives
Specific serological tests are mandatory for reliable SARSâCoVâ2 diagnostics and seroprevalence studies. Here, we assess the specificities of four commercially available SARSâCoVâ2 IgG ELISAs in serum/plasma panels originating from Africa, South America, and Europe.
Methods
882 serum/plasma samples collected from symptomâfree donors before the COVIDâ19 pandemic in three African countries (Ghana, Madagascar, Nigeria), Colombia, and Germany were analysed with three nucleocapsidâbased ELISAs (Euroimmun AntiâSARSâCoVâ2âNCP IgG, EDIâą Novel Coronavirus COVIDâ19 IgG, Mikrogen recomWell SARSâCoVâ2 IgG), one spike/S1âbased ELISA (Euroimmun AntiâSARSâCoVâ2 IgG), and inâhouse common cold CoV ELISAs.
Results
High specificity was confirmed for all SARSâCoVâ2 IgG ELISAs for Madagascan (93.4â99.4%), Colombian (97.8â100.0%), and German (95.9â100.0%) samples. In contrast, specificity was much lower for the Ghanaian and Nigerian serum panels (Ghana: NCPâbased assays 77.7â89.7%, spike/S1âbased assay 94.3%; Nigeria: NCPâbased assays 39.3â82.7%, spike/S1âbased assay 90.7%). 15 of 600 African sera were concordantly classified as positive in both the NCPâbased and the spike/S1âbased Euroimmun ELISA, but did not inhibit spike/ACE2 binding in a surrogate virus neutralisation test. IgG antibodies elicited by previous infections with common cold CoVs were found in all sample panels, including those from Madagascar, Colombia, and Germany and thus do not inevitably hamper assay specificity. Nevertheless, high levels of IgG antibodies interacting with OC43 NCP were found in all 15 SARSâCoVâ2 NCP/spike/S1 ELISA positive sera.
Conclusions
Depending on the chosen antigen and assay protocol, SARSâCoVâ2 IgG ELISA specificity may be significantly reduced in certain populations probably due to interference of immune responses to endemic pathogens like other viruses or parasites
Limited specificity of commercially available SARSâCoVâ2 IgG ELISAs in serum samples of African origin
Objectives
Specific serological tests are mandatory for reliable SARSâCoVâ2 diagnostics and seroprevalence studies. Here, we assess the specificities of four commercially available SARSâCoVâ2 IgG ELISAs in serum/plasma panels originating from Africa, South America, and Europe.
Methods
882 serum/plasma samples collected from symptomâfree donors before the COVIDâ19 pandemic in three African countries (Ghana, Madagascar, Nigeria), Colombia, and Germany were analysed with three nucleocapsidâbased ELISAs (Euroimmun AntiâSARSâCoVâ2âNCP IgG, EDIâą Novel Coronavirus COVIDâ19 IgG, Mikrogen recomWell SARSâCoVâ2 IgG), one spike/S1âbased ELISA (Euroimmun AntiâSARSâCoVâ2 IgG), and inâhouse common cold CoV ELISAs.
Results
High specificity was confirmed for all SARSâCoVâ2 IgG ELISAs for Madagascan (93.4â99.4%), Colombian (97.8â100.0%), and German (95.9â100.0%) samples. In contrast, specificity was much lower for the Ghanaian and Nigerian serum panels (Ghana: NCPâbased assays 77.7â89.7%, spike/S1âbased assay 94.3%; Nigeria: NCPâbased assays 39.3â82.7%, spike/S1âbased assay 90.7%). 15 of 600 African sera were concordantly classified as positive in both the NCPâbased and the spike/S1âbased Euroimmun ELISA, but did not inhibit spike/ACE2 binding in a surrogate virus neutralisation test. IgG antibodies elicited by previous infections with common cold CoVs were found in all sample panels, including those from Madagascar, Colombia, and Germany and thus do not inevitably hamper assay specificity. Nevertheless, high levels of IgG antibodies interacting with OC43 NCP were found in all 15 SARSâCoVâ2 NCP/spike/S1 ELISA positive sera.
Conclusions
Depending on the chosen antigen and assay protocol, SARSâCoVâ2 IgG ELISA specificity may be significantly reduced in certain populations probably due to interference of immune responses to endemic pathogens like other viruses or parasites
Performance of a rapid diagnostic test for the detection of Cryptosporidium spp. in African children admitted to hospital with diarrhea.
BackgroundCryptosporidium is a protozoan parasite that causes mild to severe diarrhoeal disease in humans. To date, several commercial companies have developed rapid immunoassays for the detection of Cryptosporidium infection. However, the challenge is to identify an accurate, simple and rapid diagnostic tool for the estimation of cryptosporidiosis burden. This study aims at evaluating the accuracy of CerTest Crypto, a commercialized rapid diagnostic test (RDT) for the detection of Cryptosporidium antigens in the stool of children presenting with diarrhoea.MethodsA cross-sectional study was conducted in four study sites in Sub-Saharan Africa (Gabon, Ghana, Madagascar, and Tanzania), from May 2017 to April 2018. Stool samples were collected from children under 5 years with diarrhoea or a history of diarrhoea within the last 24 hours. All specimens were processed and analyzed using CerTest Crypto RDT against a composite diagnostic panel involving two polymerase chain reaction (PCR) tests (qPCR and RFLP-PCR,) as the gold standard.ResultsA total of 596 stool samples were collected. Evaluation of the RDT yielded a very low overall sensitivity of 49.6% (confidence interval (CI) 40.1-59.0), a specificity of 92.5% (CI 89.8-94.7), positive predictive value of 61.3% (CI 50.6-71.2), and negative predictive value of 88.5% (85.3-91.1) when compared to the composite reference standard of qPCR and RFLP-PCR for the detection of Cryptosporidium species. Moreover, the performance of this test varied across different sites.ConclusionThe weak performance of the studied RDT suggests the need to carefully evaluate available commercial RDTs before their use as standard tools in clinical trials and community survey of Cryptosporidium infections in pediatric cohorts